Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mammalian G1 and G2 phase checkpoints

P M O'Connor1

  • 1Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Cancer Surveys
|January 1, 1997
PubMed
Summary

This review details DNA damage responses, focusing on G1 and G2 cell cycle arrest mechanisms in mammalian cells. Understanding the TP53 pathway and its role in DNA repair and cell survival is crucial for cancer therapy development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Bacillus safensis</i> APC 4099 has broad-spectrum antimicrobial activity against both bacteria and fungi and produces several antimicrobial peptides, including the novel circular bacteriocin safencin E.

Applied and environmental microbiology·2025
Same author

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.

Gut microbes·2024
Same author

Nisin variants from Streptococcus and Staphylococcus successfully express in NZ9800.

Journal of applied microbiology·2021
Same author

Molecular surveillance of measles and rubella in the WHO European Region: new challenges in the elimination phase.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

A Multibacteriocin Cheese Starter System, Comprising Nisin and Lacticin 3147 in Lactococcus lactis, in Combination with Plantaricin from Lactobacillus plantarum.

Applied and environmental microbiology·2017
Same author

Inhibition of Listeria monocytogenes biofilms by bacteriocin-producing bacteria isolated from mushroom substrate.

Journal of applied microbiology·2016

Area of Science:

  • Cellular and Molecular Biology
  • Genetics and Genomics
  • Cancer Research

Background:

  • Mammalian cells possess intricate mechanisms to arrest the cell cycle at G1 and G2 phases following DNA damage.
  • The tumor suppressor protein TP53 (also known as p53) plays a central role in these responses, regulating numerous downstream genes.
  • The precise molecular events governing G1 and G2 arrest, including the involvement of p21 and the cyclin B1/CDC2 kinase complex, are complex and context-dependent.

Purpose of the Study:

  • To explore the mechanisms of DNA damage-induced G1 and G2 arrest in mammalian cells.
  • To highlight the complexity of the TP53 pathway and its regulated genes, such as p21.
  • To discuss the factors influencing cell survival outcomes after TP53 activation and the potential for targeting TP53-defective cancer cells.

Main Methods:

  • Review of existing literature on DNA damage response pathways.
  • Analysis of the roles of key proteins like TP53, p21, cyclin B1, and CDC2 in cell cycle regulation.
  • Exploration of the interplay between DNA damage sensing and cell cycle checkpoint activation.

Main Results:

  • TP53 regulates diverse genes, with p21 implicated in G1 arrest and potentially DNA repair.
  • Cellular context and DNA damaging agent type significantly influence TP53's impact on cell survival.
  • DNA damage suppresses cyclin B1/CDC2 kinase activation, possibly via inhibitory phosphorylations and reduced cyclin B1 levels, affecting G2 arrest.
  • The precise interaction point in the CDC2-CDC25C loop for G2 arrest remains to be fully elucidated.

Conclusions:

  • Further research is needed to fully understand the TP53 pathway and its role in DNA repair and cell cycle control.
  • Identifying upstream components of the G2 checkpoint could reveal novel therapeutic targets.
  • Targeting vulnerabilities in TP53-defective cancer cells, potentially through G2 checkpoint abrogators, offers a promising strategy for anti-cancer drug discovery.

Related Experiment Videos